Ipsen reports 11.6% sales growth in Q1 2025, confirms full-year guidance, submits drug for approval.

From GlobeNewswire: 2025-04-16 00:57:00

Ipsen reported a strong start to 2025 with total sales growth of 11.6% at CER and 11.7% as reported, driven by all three therapeutic areas. Tovorafenib submitted for pediatric low-grade glioma to EMA. Full-year 2025 financial guidance confirmed, including total sales growth over 5.0% and core operating margin over 30.0%. Key milestones expected in 2025 include regulatory decision for Cabometyx and proof-of-concept data readout for LANT3. Ipsen successfully completed a €500 million bond transaction. Conference call and webcast for investors and analysts scheduled for today at 2pm CET. Half-year results to be published on July 31st, 2025. Company’s focus on Oncology, Rare Disease, and Neuroscience with global presence. Forward-looking statements and disclaimers provided regarding financial targets and potential risks.



Read more at GlobeNewswire:: Ipsen delivers strong sales in the first quarter 2025 and